Investor Presentation
Q3 2022 Earnings
Curt R. Hartman
Chair of the Board, President, and Chief Executive Officer
Todd W. Garner
Executive Vice President and Chief Financial Officer
October 26, 2022
Forward-Looking Information
This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks
and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this presentation involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those
expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this presentation include, but are not limited to, the risks posed to the Company's business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability; any assumptions underlying any of the foregoing, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2021 and other risks and uncertainties which may be detailed from time to time in reports filed by CONMED with the SEC.
Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles in the United States (GAAP). The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performancemeasures prepared in accordance with GAAP.
2
CONMED Vision |
Empower healthcare providers worldwide to deliver |
exceptional outcomes for patients. |
Focus behind the Vision |
People, Products, Profitability |
3 |
Objectives for Our Shareholders |
▪ Aggregate growthand profitability over the long term to significantly |
increase the valuation of the company |
▪ Increase our market sharein large and attractive markets |
▪ Deliver above-marketrevenueand profitability growthover the long term |
4 |
Orthopedics: Large, Attractive Markets | |||||||
Category | Description | Market Size and Competitors | Dollar Value of 1 Market Share Point | ||||
Sports | $4.4 to $4.6 Billion | ||||||
Devices for repair of soft | ▪ | Arthrex | ▪ | Stryker | ~$45M | ||
Medicine | tissue injuries in joints | ▪ | DePuy Mitek (J&J) | ||||
▪ | ▪ | Zimmer Biomet | |||||
Smith & Nephew | |||||||
Allograft | Exclusive commercial | $375 to $425 Million | |||||
2022 Sept YTD | ▪ | Allosource | ~$4M | ||||
rights to MTF allograft | |||||||
Tissue | ▪ | LifeNet | |||||
tissue | ▪ | RTI | |||||
Surgical drills and saws | $1.4 to $1.6 Billion | ||||||
Powered | ▪ | DePuy Synthes (J&J) | ~$15M | ||||
with related single-use | ▪ | ||||||
Stryker | |||||||
Instruments | accessories | ▪ | Medtronic (Midas Rex / Xomed) | ||||
US | ▪ | Zimmer Biomet | |||||
36% | High-definition surgical | $1.8 to $2.0 Billion | |||||
Surgical | ▪ | Stryker | |||||
International | visualization systems to | ▪ | Olympus | ~$19M | |||
Visualization | enable minimally invasive | ▪ | Arthrex | ▪ | Richard Wolf | ||
64% | ▪ | Karl Storz | ▪ | ||||
Smith & Nephew | |||||||
arthroscopic surgery | |||||||
Comprehensive portfolio | $4.4 to $4.6 Billion | ||||||
▪ | Stryker | ||||||
74% | Foot and | includes implants, | ▪ | DePuy Synthes | ~45M | ||
fracture systems, | ▪ | Paragon 28 | |||||
(J&J) | |||||||
Ankle | ▪ | ||||||
Recurring, single-use revenue | biologics, and related | ▪ | Arthrex | Treace | |||
hardware | |||||||
Total | ~$128M | ||||||
60% to 70% in Surgery Centers in the U.S. | ~13% growth for total | ||||||
Orthopedics | |||||||
company | |||||||
5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
CONMED Corporation published this content on 26 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2022 20:19:21 UTC.